<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="442831" id="root" date="1997-03-14" xml:lang="en">
<title>USA: Agouron gets FDA clearance to market AIDS drug.</title>
<headline>Agouron gets FDA clearance to market AIDS drug.</headline>
<dateline>LA JOLLA, Calif.</dateline>
<text>
<p>Agouron Pharmaceuticals Inc. said Friday the U.S. Food and Drug Administration gave it clearance to market its HIV protease inhibitor Viracept in the United States.</p>
<p>Approval was given under the FDA's accelerated approval process, Agouron said.</p>
<p>Stock of the La Jolla, Calif.-based pharmaceutical maker rose $6 to $81.75 in afternoon trading on Nasdaq.</p>
<p>Viracept is the first HIV protease inhibitor to be cleared for marketing simultaneously in formulations for adults and children.  Agouron said it will be widely available at pharmacies throughout the United States next week.</p>
<p>Viracept, which was developed by Agouron in collaboration with the pharmaceutical division of Japan Tobacco Inc., is a retroviral therapy for HIV, the virus that causes AIDS.</p>
<p>The wholesale price of Viracept will be $15.48 a day or $5,650 for a 365-day supply at the recommended dose of 750 mg three times daily.</p>
<p>Agouron has established a patient assistance programme to help people in need pay for Viracept. It said it will provide the drug without charge to those patients whose need is greatest and who are least able to pay for the drug.</p>
<p>In addition, Agouron will provide Viracept without charge to any child in the United States who is not covered by public or private health insurance, the company said.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
  <code code="C21">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
  <code code="GCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
  <code code="GHEA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-03-14"/>
  </code>
</codes>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-03-14"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="LA JOLLA, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
